Premium
Effects of selenium supplementation on pregnancy outcomes and disease progression in HIV‐infected pregnant women in Lagos: A randomized controlled trial
Author(s) -
Okunade Kehinde S.,
Olowoselu Olusola F.,
JohnOlabode Sarah,
Hassan Basirat O.,
Akinsola Oluwatosin J.,
Nwogu Chidinma M.,
Ugwu Aloy O.,
Moses Olusanjo E.,
Rabiu Kabiru A.,
Ajepe Adegbenga,
Adenekan Muisi A.,
Adejimi Adebola A.,
Akanmu Sulaimon A.,
Kanki Phyllis J.
Publication year - 2021
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1002/ijgo.13514
Subject(s) - medicine , pregnancy , randomized controlled trial , placebo , relative risk , confidence interval , obstetrics , adverse effect , selenium , clinical trial , pediatrics , genetics , alternative medicine , materials science , pathology , metallurgy , biology
Abstract Objective To examine the effects of selenium supplementation on pregnancy outcomes and disease progression among HIV‐infected pregnant women in Lagos. Methods A randomized, placebo‐controlled trial conducted among HIV‐positive pregnant women between September 2018 and August 2019. At enrollment, 90 women were randomly assigned into each treatment arm to receive either a daily tablet of 200 μg elemental selenium or a placebo. Relevant participants' sociodemographic and clinical data were collected at enrollment and delivery. Results Women in the selenium arm had a significantly lower risk of preterm delivery (relative risk [RR] 0.32, 95% confidence interval [CI] 0.11–0.96) and a non‐significant reduction in the risk of delivering term neonates with a low delivery weight (RR 0.24, 95% CI 0.05–1.19). Supplemental selenium does not increase the risk of perinatal death and adverse drug events. Conclusion The study reported a beneficial effect of prenatal selenium supplements on the risk of preterm delivery with no further reduction in risk among HIV‐infected women who used the supplements for more than 14 weeks. Trial registration Pan African Clinical Trial Registry (PACTR201809756724274).